I believe your assessment is substantially correct.
Considering the global attention that the media gave the Georgetown lipid assay test it still amazes me that Amarantus was able to secure an option to license the test. It demonstrates just how well connected and respected the company's management team is in the emerging field of Alzheimer's diagnostics.
I think a combination of the two tests will move the S & S numbers to the 95% range. If that happens Amarantus will control the "gold standard" for diagnosing Alzheimer's.
Spinning off the diagnostics division will be one of the key factors in making 2015 the "monumental year" of which Gerald has spoken.
p.s. It's the message that is important, not the messenger.